Current HIV/AIDS Reports

, Volume 14, Issue 2, pp 47–53 | Cite as

Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV

HIV Pathogenesis and Treatment (AL Landay and N Utay, Section Editors)
  • 711 Downloads
Part of the following topical collections:
  1. Topical Collection on HIV Pathogenesis and Treatment

Abstract

Abnormal liver enzymes (LE) are common in patients infected with the human immunodeficiency virus (HIV) even in the absence of viral hepatitis or alcohol abuse. With availability of antiretroviral combination therapy, life expectancy has improved dramatically and as a consequence the spectrum of liver disease is changing. Increased reports on the development of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH) in HIV coinfected patients raise questions around prevalence, clinical manifestations, and clinical outcome of these liver diseases in HIV coinfection. Moreover, the potential impact of combination antiretroviral therapy as well as direct HIV effects on the emergence of non-alcoholic fatty liver disease needs to be explored. This review summarizes the recent literature on NAFLD and NASH in HIV.

Keywords

Liver fibrosis Nash NAFLD HIV 

Notes

Acknowledgements

This work was supported by the DZIF TTU HIV Project 05.803 and the German Center for Infection Research (DZIF).

Compliance with Ethical Standards

Conflict of Interest

Jürgen Kurt Rockstroh reports honoraria for speaking at educational events or consulting from Abbott, Abbvie, Bionor, BMS, Cipla, Gilead, Hexal, Janssen, Merck, and ViiV.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    Serrano-Villar S, Gutiérrez F, Miralles C, et al. Human immunodeficiency virus as a chronic disease: evaluation and management of nonacquired immune deficiency syndrome-defining conditions. Open Forum Infect Dis. 2016;3(2):ofw097.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis. 2015;2(1):ofv015.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    •• Morse CG, McLaughlin M, Matthews L, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis. 2015;60(10):1569–78.2. One of the few liver biopsy studies in HIV-infected adults with aminotransferase levels elevated above the upper limit of normal for ≥6 months while receiving ART, and without chronic viral hepatitis or other known causes of chronic liver disease. Interestingly, HIV-infected adults with chronic aminotransferase elevations while receiving ART had a high rate of liver disease (55% NASH) PubMedPubMedCentralGoogle Scholar
  4. 4.
    Macias J, Rivero-Juarez A, Neukam K, et al. HEPAVIR study group. Impact of genetic polymorphisms associated with nonalcoholic fatty liver disease on HIV-infected individuals. AIDS. 2015;29(15):1927–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Price JC, Seaberg EC, Latanich R, et al. Risk factors for fatty liver in the multicenter AIDS cohort study. Am J Gastroenterol. 2014;109(5):695–704.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rivero-Juárez A, Camacho A, Merchante N, et al. Grupo para el estudio de las hepatitis vı’ricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI). Incidence of liver damage of uncertain origin in HIV patients not co-infected with HCV/HBV. PLoS One. 2013;8(7):e68953.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Crum-Cianflone N, Dilay A, Collins G, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr. 2009;50(5):464–73.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ingiliz P, Valantin MA, Duvivier C, et al. Liver damage underlying unexplained aminotransferase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology. 2009;49:436–42.CrossRefPubMedGoogle Scholar
  9. 9.
    •• European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. Clinically extremely useful guidelines around all major aspects of fatty liver disease including disease definitions and treatment recommendations . Google Scholar
  10. 10.
    Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: a prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol. 2013;47:182–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Vuille-Lessard É, Lebouché B, Lennox L, et al. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients. AIDS. 2016;30:2635–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Trépo E, Romeo S, Zucman-Rossi J, Nahon P. PNPLA3 gene in liver diseases. J Hepatol. 2016;65:399–412.CrossRefPubMedGoogle Scholar
  14. 14.
    Macías J, Real LM, Rivero-Juárez A, et al. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients. HIV Med. 2016.Google Scholar
  15. 15.
    Vodkin I, Valasek MA, Bettencourt R, et al. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41(4):368–78.CrossRefPubMedGoogle Scholar
  16. 16.
    Scheiner B, Mandorfer M, Schwabl P, et al. The impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS One. 2015;10(11):e0143429.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    •• Jiménez-Sousa MA, Berenguer J, García-Álvarez M, et al. Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. AIDS. 2016;30(3):465–70. This cross-sectional study analyses the association between patatin-like phospholipase domain-containing 3 gene (PNPLA3) rs738409 polymorphism and severity of liver disease in HIV/hepatitis C virus-coinfected patient. Indeed, PNPLA3 rs738409 polymorphism was associated with the severity of liver fibrosis in patients coinfected with HIV and hepatitis C virus, suggesting that this polymorphism might also play a significant role in the progression of hepatic fibrosis in this group of patients CrossRefPubMedGoogle Scholar
  18. 18.
    Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5(9):782–94.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lelouvier B, Servant F, Païssé S, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology. 2016; doi: 10.1002/hep.28829.PubMedGoogle Scholar
  20. 20.
    Dillon SM, Frank DN, Wilson CC. The gut microbiome and HIV-1 pathogenesis: a two way street. AIDS. 2016;14.Google Scholar
  21. 21.
    Liu JP, Zou WL, Chen SJ, et al. Effects of different diets on intestinal microbiota and nonalcoholic fatty liver disease development. World J Gastroenterol. 2016;22(32):7353–64.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Rial SA, Karelis AD, Bergeron KF, et al. Gut microbiota and metabolic health: the potential beneficial effects of a medium chain triglyceride diet in obese individuals. Nutrients. 2016;8(5).Google Scholar
  23. 23.
    Houghton D, Thoma C, Hallsworth K, et al. Exercise reduces liver lipids and visceral adiposity in patients with nonalcoholic steatohepatitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2016.Google Scholar
  24. 24.
    Pérez-Matute P, Pérez-Martínez L, Aguilera-Lizarraga J, et al. Maraviroc modifies gut microbiota composition in a mouse model of obesity: a plausible therapeutic option to prevent metabolic disorders in HIV-infected patients. Rev Esp Quimioter. 2015;28(4):200–6.PubMedGoogle Scholar
  25. 25.
    Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;16:F1–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Noor MA, Parker RA, O’Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS. 2004;18:2137–44.CrossRefPubMedGoogle Scholar
  27. 27.
    Shlay JC, Visnegarwala F, Bartsch G, et al. Terry Beirn community programs for clinical research on AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147–55.CrossRefPubMedGoogle Scholar
  28. 28.
    Pedersen KK, Pedersen M, Trøseid M, et al. Microbial translocation in HIV infection is associated with dyslipidemia, insulin resistance, and risk of myocardial infarction. J Acquir Immune Defic Syndr. 2013;64:425–33.CrossRefPubMedGoogle Scholar
  29. 29.
    Adeyemi OM, Livak B, Orsi J, et al. Vitamin D and insulin resistance in non-diabetic women's interagency HIV study participants. AIDS Patient Care STDs. 2013;27:320–5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS. 2006;20:387–95.CrossRefPubMedGoogle Scholar
  31. 31.
    Guaraldi G, Squillace N, Stentarelli C, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis. 2008;47:250–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Akhtar MA, Mathieson K, Arey B, et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol. 2008;20:1194–204.CrossRefPubMedGoogle Scholar
  33. 33.
    Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat. 2011;18:11–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Stankov MV, Panayotova-Dimitrova D, Leverkus M, Vondran FW, Bauerfeind R, Binz A, Behrens GM. Autophagy inhibition due to thymidine analogues as novel mechanism leading to hepatocyte dysfunction and lipid accumulation. AIDS. 2012;26:1995–2006.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  1. 1.Department of Medicine IUniversity Hospital BonnBonnGermany
  2. 2.German Centre for Infection Research (DZIF), Partner Site Bonn-CologneBonnGermany

Personalised recommendations